CovidChloroV1, Main, Corpus, bibRecord, 000542

Can we use hydroxychloroquine to treat COVID-19 now?

Identifieur interne : 000542 ( Main/Corpus ); précédent : 000541; suivant : 000543

Can we use hydroxychloroquine to treat COVID-19 now?

Auteurs : Jun Chen ; Danping Liu ; Lin Yin ; Lijun Zhang ; Hongzhou Lu

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2021.

RBID : pubmed:33408016

English descriptors

KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (virology), Clinical Trials as Topic (MeSH), Drug Combinations (MeSH), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Indoles (therapeutic use), Interferon-alpha (therapeutic use), Lopinavir (therapeutic use), Ritonavir (therapeutic use), SARS-CoV-2 (pathogenicity), Uncertainty (MeSH).
MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Antiviral Agents, Azithromycin, Hydroxychloroquine, Indoles, Interferon-alpha, Lopinavir, Ritonavir.
- drug therapy : COVID-19.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19.
- Clinical Trials as Topic, Drug Combinations, Drug Repositioning, Humans, Uncertainty.

DOI: 10.1016/j.ijantimicag.2020.106173
PubMed: 33408016
PubMed Central: PMC7834540

Links to Exploration step

pubmed:33408016

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can we use hydroxychloroquine to treat COVID-19 now?</title>
<author><name sortKey="Chen, Jun" sort="Chen, Jun" uniqKey="Chen J" first="Jun" last="Chen">Jun Chen</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Danping" sort="Liu, Danping" uniqKey="Liu D" first="Danping" last="Liu">Danping Liu</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yin, Lin" sort="Yin, Lin" uniqKey="Yin L" first="Lin" last="Yin">Lin Yin</name>
<affiliation><nlm:affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Lijun" sort="Zhang, Lijun" uniqKey="Zhang L" first="Lijun" last="Zhang">Lijun Zhang</name>
<affiliation><nlm:affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: luhongzhou@fudan.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33408016</idno>
<idno type="pmid">33408016</idno>
<idno type="doi">10.1016/j.ijantimicag.2020.106173</idno>
<idno type="pmc">PMC7834540</idno>
<idno type="wicri:Area/Main/Corpus">000542</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000542</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Can we use hydroxychloroquine to treat COVID-19 now?</title>
<author><name sortKey="Chen, Jun" sort="Chen, Jun" uniqKey="Chen J" first="Jun" last="Chen">Jun Chen</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Danping" sort="Liu, Danping" uniqKey="Liu D" first="Danping" last="Liu">Danping Liu</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yin, Lin" sort="Yin, Lin" uniqKey="Yin L" first="Lin" last="Yin">Lin Yin</name>
<affiliation><nlm:affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Lijun" sort="Zhang, Lijun" uniqKey="Zhang L" first="Lijun" last="Zhang">Lijun Zhang</name>
<affiliation><nlm:affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: luhongzhou@fudan.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Indoles (therapeutic use)</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Uncertainty (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
<term>Indoles</term>
<term>Interferon-alpha</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Combinations</term>
<term>Drug Repositioning</term>
<term>Humans</term>
<term>Uncertainty</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33408016</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>57</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Can we use hydroxychloroquine to treat COVID-19 now?</ArticleTitle>
<Pagination><MedlinePgn>106173</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30379-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106173</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Danping</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yin</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Lijun</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Hongzhou</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: luhongzhou@fudan.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>93M09WW4RU</RegistryNumber>
<NameOfSubstance UI="C086979">umifenovir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035501" MajorTopicYN="N">Uncertainty</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>5</Hour>
<Minute>53</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33408016</ArticleId>
<ArticleId IdType="pii">S0924-8579(20)30379-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106173</ArticleId>
<ArticleId IdType="pmc">PMC7834540</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2012 Jul 25;308(4):353-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22820788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:320-327</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29207305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000542 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000542 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33408016
   |texte=   Can we use hydroxychloroquine to treat COVID-19 now?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33408016" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Can we use hydroxychloroquine to treat COVID-19 now?

Can we use hydroxychloroquine to treat COVID-19 now?

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki